Vertex Pharma (VRTX) stock slips as UnitedHealth (UNH) offers its pain drug Journavx Tier 3 coverage, setting a rivalry with ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in expanding its market ...

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

Positive data from a pair of acute pain studies convinced the company that its drug, which works differently than existing ...

Tris Pharma’s opioid alternative has scored a third win in a trio of clinical trials, providing the biotech with the data ...

Here's why four Motley Fool contributors think chip giants Nvidia ( NVDA -0.26%) and Micron Technologies ( MU -1.05%), travel services company Airbnb ( ABNB -0.83%), biotech behemoth Vertex ...

Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

The encouraging result comes just days after the US FDA approved Vertex Pharma's non-opioid painkiller Journavx (suzetrigine), an oral NaV1.8 inhibitor, as a treatment for acute pain, representing ...

In the second world war, the physician Henry Beecher observed that some of his soldier patients, despite being injured on the ...

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

Optum, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in an ...